Switzerland - Perancis - Swissmedic (Swiss Agency for Therapeutic Products)

om pharma sa - haemophili influenzae lysatum, diplocoques pneumoniae lysatum, klebsiellae pneumoniae et ozaenae lysatum, les staphylocoques dorés lysatum, streptocoques pyogen. et viridantis lysatum, jruby catarrhalis lysatum - enfants, gouttes orales - lysatum bacteriorum lyophilisatum 3,5 mg corresp. haemophili influenzae lysatum et diplocoques pneumoniae lysatum et klebsiellae pneumoniae et ozaenae lysatum et les staphylocoques dorés lysatum et les streptocoques pyogen. et viridantis lysatum et jruby catarrhalis lysatum, conserv.: propylis parahydroxybenzoas, e 218, arom.: saccharinum natricum, natrii cyclamas, excipiens ad solution de 0,32 ml corresp. 10 gouttes. - stimulant du système immunitaire lors d'infections du système respiratoire et de bronchite chronique - les bactéries et hefepräparate

Kanada - Perancis - Health Canada

smiths medical asd inc - eau - liquide - 100% - eau 100% - eent drugs, miscellaneous

Belgium - Perancis - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tilman sa-nv - echinacea purpurea l. moench. jus 180 mg - comprimé pelliculé - echinacea purpurea l. moench. jus 180 mg - other respiratory system products; l03ax other immunostimulants

Kesatuan Eropah - Perancis - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibrose kystique - autres produits du système respiratoire - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Kesatuan Eropah - Perancis - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, l'ivacaftor - fibrose kystique - autres produits du système respiratoire - orkambi comprimés est indiqué pour le traitement de la fibrose kystique (fk) chez les patients âgés de 6 ans et plus qui sont homozygotes pour la mutation f508del du gène cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Switzerland - Perancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - comprimés pelliculés - ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, lactosum monohydricum 167.2 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 132, cera carnauba, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro compresso obducto corresp. natrium 1.82 mg. - la mucoviscidose - synthetika

Switzerland - Perancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - lumacaftorum, ivacaftorum - comprimés pelliculés - lumacaftorum 200 mg, ivacaftorum 125 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, povidonum k 30, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 120, e 132, e 133, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro compresso obducto corresp. natrium 3.51 mg. - la mucoviscidose - synthetika

Switzerland - Perancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - granulat - ivacaftorum 50 mg, hypromellosi acetas succinas, natrii laurilsulfas, lactosum monohydricum 73.2 mg, mannitolum, sucralosum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas ad granulatum pro charta corresp. natrium 0.99 mg. - la mucoviscidose - synthetika

Switzerland - Perancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - granulat - ivacaftorum 75 mg, hypromellosi acetas succinas, natrii laurilsulfas, lactosum monohydricum 109.8 mg, mannitolum, sucralosum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas ad granulatum pro charta corresp. natrium 1.49 mg. - la mucoviscidose - synthetika

Kanada - Perancis - Health Canada

ino therapeutics - monoxyde d'azote - gaz - 100ppm - monoxyde d'azote 100ppm - nitrates and nitrites